X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs BIOCON LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA BIOCON LTD GLENMARK PHARMA/
BIOCON LTD
 
P/E (TTM) x 12.0 76.7 15.6% View Chart
P/BV x 3.2 7.2 43.9% View Chart
Dividend Yield % 0.4 0.2 221.7%  

Financials

 GLENMARK PHARMA   BIOCON LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
BIOCON LTD
Mar-17
GLENMARK PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs9931,162 85.5%   
Low Rs729483 151.2%   
Sales per share (Unadj.) Rs325.5194.6 167.3%  
Earnings per share (Unadj.) Rs39.334.4 114.2%  
Cash flow per share (Unadj.) Rs48.748.3 100.8%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.20.1 191.0%  
Book value per share (Unadj.) Rs159.2241.9 65.8%  
Shares outstanding (eoy) m282.17200.00 141.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.2 62.6%   
Avg P/E ratio x21.923.9 91.7%  
P/CF ratio (eoy) x17.717.0 103.9%  
Price / Book Value ratio x5.43.4 159.1%  
Dividend payout %5.12.9 175.1%   
Avg Mkt Cap Rs m242,991164,440 147.8%   
No. of employees `00013.09.2 140.4%   
Total wages/salary Rs m16,4087,470 219.7%   
Avg. sales/employee Rs Th7,083.94,213.9 168.1%   
Avg. wages/employee Rs Th1,265.4809.0 156.4%   
Avg. net profit/employee Rs Th855.1745.2 114.7%   
INCOME DATA
Net Sales Rs m91,85738,911 236.1%  
Other income Rs m3741,571 23.8%   
Total revenues Rs m92,23040,482 227.8%   
Gross profit Rs m20,3679,795 207.9%  
Depreciation Rs m2,6442,772 95.4%   
Interest Rs m2,373260 912.8%   
Profit before tax Rs m15,7248,334 188.7%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8271,616 236.8%   
Profit after tax Rs m11,0886,881 161.1%  
Gross profit margin %22.225.2 88.1%  
Effective tax rate %24.319.4 125.5%   
Net profit margin %12.117.7 68.3%  
BALANCE SHEET DATA
Current assets Rs m68,74640,477 169.8%   
Current liabilities Rs m27,02716,783 161.0%   
Net working cap to sales %45.460.9 74.6%  
Current ratio x2.52.4 105.5%  
Inventory Days Days8560 142.6%  
Debtors Days Days9683 115.3%  
Net fixed assets Rs m24,13245,073 53.5%   
Share capital Rs m2821,000 28.2%   
"Free" reserves Rs m44,64347,377 94.2%   
Net worth Rs m44,92548,377 92.9%   
Long term debt Rs m45,36321,082 215.2%   
Total assets Rs m117,63993,942 125.2%  
Interest coverage x7.633.1 23.1%   
Debt to equity ratio x1.00.4 231.7%  
Sales to assets ratio x0.80.4 188.5%   
Return on assets %11.47.6 150.5%  
Return on equity %24.714.2 173.5%  
Return on capital %19.112.6 151.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15212,988 432.3%   
Fx outflow Rs m8,0847,899 102.3%   
Net fx Rs m48,0685,089 944.5%   
CASH FLOW
From Operations Rs m6,5746,400 102.7%  
From Investments Rs m-7,124-4,985 142.9%  
From Financial Activity Rs m5,432-1,775 -306.0%  
Net Cashflow Rs m1,992-473 -421.2%  

Share Holding

Indian Promoters % 48.3 40.4 119.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 6.9 8.4 82.1%  
FIIs % 34.4 10.7 321.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.9 52.8%  
Shareholders   56,727 109,995 51.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  J.B.CHEMICALS  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS